Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantheus Holdings (NQ: LNTH )

101.98 -3.36 (-3.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lantheus Holdings

< Previous 1 2 3 Next >
Lantheus Appoints Julie Eastland as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports Second Quarter 2024 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
The IWM ETF broke above multi-year resistance last week, driven by lower-than-expected June inflation data, leading to a weekly gain of 6.11%. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease
Acquisition Expands Pipeline and Strengthens Alzheimer’s Diagnostic Capabilities 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Welcomes CMS’ Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Appoints Jamie Spaeth as Chief People Officer
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
Deal Further Strengthens Lantheus’ Prostate Cancer Portfolio and Expands Pipeline to Include Breast Cancer 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform
The integrated aPROMISE solution to be demonstrated on Siemens Healthineers’ syngo.via platform at the SNMMI annual meeting 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the William Blair 44th Annual Growth Stock Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Insider Trading is Good News for These Stocks
Insiders are buying these hot stocks that have ample upside for investors. The list includes pharma, entertainment, and financial stocks and Berkshire buys. 
Via MarketBeat
Lantheus Announces Executive Appointments to Accelerate Innovation
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports First Quarter 2024 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
DEFINITY is the #1 utilized ultrasound enhancing agent in the U.S. for patients with suboptimal echocardiograms 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces CEO Succession Plan
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the Jefferies London Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports Third Quarter 2023 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.